[{"address1": "Cedar Brook Corporate Center", "address2": "4-B Cedar Brook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 495 2200", "fax": "609 495 2202", "website": "https://palatin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.", "fullTimeEmployees": 34, "irWebsite": "http://www.palatin.com/investorcenter/overview.asp", "maxAge": 86400, "priceHint": 4, "previousClose": 1.88, "open": 1.84, "dayLow": 1.8, "dayHigh": 1.96, "regularMarketPreviousClose": 1.88, "regularMarketOpen": 1.84, "regularMarketDayLow": 1.8, "regularMarketDayHigh": 1.96, "beta": 0.939, "forwardPE": -1.601695, "volume": 136480, "regularMarketVolume": 136480, "averageVolume": 383177, "averageVolume10days": 93950, "averageDailyVolume10Day": 93950, "bidSize": 800, "askSize": 3000, "marketCap": 30498174, "fiftyTwoWeekLow": 1.43, "fiftyTwoWeekHigh": 5.65, "priceToSalesTrailing12Months": 5.1674104, "fiftyDayAverage": 1.9522, "twoHundredDayAverage": 2.3143, "currency": "USD", "enterpriseValue": 21190842, "floatShares": 15836660, "sharesOutstanding": 16136600, "sharesShort": 1290908, "sharesShortPriorMonth": 1390863, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.08, "heldPercentInsiders": 0.041389998, "heldPercentInstitutions": 0.07699, "shortRatio": 5.51, "shortPercentOfFloat": 0.081499994, "impliedSharesOutstanding": 16136600, "bookValue": 0.098, "priceToBook": 19.285715, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -34810276, "trailingEps": -2.72, "forwardEps": -1.18, "lastSplitFactor": "1:25", "lastSplitDate": 1661904000, "enterpriseToRevenue": 3.59, "enterpriseToEbitda": -0.653, "52WeekChange": -0.0869565, "SandP52WeekChange": 0.26238096, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PTN", "underlyingSymbol": "PTN", "shortName": "Palatin Technologies, Inc.", "longName": "Palatin Technologies, Inc.", "firstTradeDateEpochUtc": 876922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef61cf2b-791e-37b7-b04c-9ccb76a1630d", "messageBoardId": "finmb_32651", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.89, "targetHighPrice": 17.0, "targetLowPrice": 3.0, "targetMeanPrice": 8.67, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 10014088, "totalCashPerShare": 0.621, "ebitda": -32432260, "totalDebt": 706641, "quickRatio": 1.174, "currentRatio": 1.203, "totalRevenue": 5902023, "debtToEquity": 44.754, "revenuePerShare": 0.439, "returnOnAssets": -1.10666, "returnOnEquity": -6.23201, "freeCashflow": -17958548, "operatingCashflow": -33742404, "operatingMargins": -5.55241, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]